Penumbra (PEN) to Release Quarterly Earnings on Wednesday

Penumbra (NYSE:PEN - Get Free Report) is projected to announce its earnings results after the market closes on Wednesday, April 23rd. Analysts expect the company to announce earnings of $0.66 per share and revenue of $315.72 million for the quarter. Penumbra has set its FY 2025 guidance at EPS.Persons that wish to register for the company's earnings conference call can do so using this link.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The firm had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. On average, analysts expect Penumbra to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Penumbra Stock Performance

Penumbra stock traded down $1.17 during trading on Friday, reaching $276.62. The company had a trading volume of 326,817 shares, compared to its average volume of 413,769. The firm's 50-day simple moving average is $275.47 and its 200 day simple moving average is $251.25. Penumbra has a 52 week low of $148.00 and a 52 week high of $310.00. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $10.70 billion, a price-to-earnings ratio of 813.60, a price-to-earnings-growth ratio of 2.83 and a beta of 0.56.

Insider Activity at Penumbra

In other news, CEO Adam Elsesser sold 16,560 shares of the firm's stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $274.35, for a total value of $4,543,236.00. Following the completion of the sale, the chief executive officer now owns 63,911 shares in the company, valued at approximately $17,533,982.85. This trade represents a 20.58 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Maggie Yuen sold 2,000 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $286.00, for a total transaction of $572,000.00. Following the transaction, the chief financial officer now owns 15,243 shares in the company, valued at $4,359,498. The trade was a 11.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 127,846 shares of company stock valued at $35,779,187. Insiders own 5.00% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Wells Fargo & Company increased their target price on shares of Penumbra from $275.00 to $305.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. JPMorgan Chase & Co. upped their target price on shares of Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. Needham & Company LLC reissued a "hold" rating on shares of Penumbra in a report on Wednesday, February 19th. Canaccord Genuity Group upped their price objective on Penumbra from $323.00 to $340.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Finally, Bank of America assumed coverage on Penumbra in a research report on Friday, March 14th. They set a "buy" rating and a $320.00 target price for the company. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Penumbra presently has an average rating of "Moderate Buy" and an average target price of $293.93.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.